2005
Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H, Bérégi JP. Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial. Journal Of Vascular And Interventional Radiology 2005, 16: 331-338. PMID: 15758128, DOI: 10.1097/01.rvi.0000151260.74519.ca.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stent groupStent groupBare stent groupMean lumen diameterSignificant differencesLumen diameterSuperficial femoral artery diseaseSuperficial femoral artery obstructionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionAnkle-brachial indexBinary restenosis rateDouble-blind studySymptoms of claudicationBare nitinol stentsSirolimus-eluting stentsStandard interventional techniquesArtery obstructionPrimary endpointII trialAdverse eventsAngiographic outcomesArtery diseaseLimb ischemia
2004
Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results.
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi JP. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Journal Of Invasive Cardiology 2004, 16 Suppl A: 15a-19a. PMID: 23573600.Peer-Reviewed Original ResearchConceptsMean percent diameter stenosisSirolimus-eluting stent groupSerious adverse eventsFemoral artery occlusionPercent diameter stenosisStent groupArtery occlusionAdverse eventsArtery diseaseDiameter stenosisSuperficial femoral artery diseaseSuperficial femoral artery obstructionPoor long-term outcomesSuperficial femoral artery occlusionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionSuccessful guidewire passageUncoated-stent groupPrimary end pointFemoropopliteal artery diseaseSix-month resultsLong-term outcomesSirolimus-eluting stentsMean lumen diameter
2002
Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi J. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease. Circulation 2002, 106: 1505-1509. PMID: 12234956, DOI: 10.1161/01.cir.0000029746.10018.36.Peer-Reviewed Original ResearchConceptsMean percent diameter stenosisSirolimus-eluting stent groupSerious adverse eventsFemoral artery occlusionPercent diameter stenosisStent groupArtery occlusionAdverse eventsArtery diseaseDiameter stenosisSuperficial femoral artery diseaseSuperficial femoral artery obstructionPoor long-term outcomesSuperficial femoral artery occlusionChronic limb ischemiaFemoral artery diseaseFemoral artery obstructionSuccessful guidewire passageUncoated-stent groupPrimary end pointFemoropopliteal artery diseaseLong-term outcomesSirolimus-eluting stentsMean lumen diameterNitinol self-expanding stents